Tempus AI jumps as investors focus on new “Active Follow-Up” workflow and Needham conference visibility

Tempus AI, Inc. (TEM) is up 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a cluster of fresh company updates that may be improving near-term sentiment: a newly launched automated clinical update workflow for oncology providers and heightened investor attention around management’s participation at an investor conference. Recent partnership headlines in life sciences (including an expanded oncology R&D collaboration) may also be contributing to momentum.

Details:

Tempus announced an automated “Active Follow-Up” service designed to keep therapy guidance current as clinical guidelines and approvals change, with notifications delivered through its Hub physician portal.

The company framed the service as a way to reduce the risk that a genomic report becomes outdated over the course of treatment, without requiring a new patient sample.

Tempus disclosed that its CFO was scheduled to participate in a fireside discussion at the Needham Virtual Healthcare Conference on Tuesday, April 14 (11:45 a.m. ET), which can draw incremental trading interest.

Earlier this month, Tempus also announced an expanded collaboration that provides a large biopharma partner enterprise-wide access to its AI-driven Lens platform for oncology work involving real-world evidence and related analytics services.

Sources:

Tempus, Tempus Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TEM Insider Trading Activity

$TEM insiders have traded $TEM stock on the open market 97 times in the past 6 months. Of those trades, 0 have been purchases and 97 have been sales.

Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:

ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 57 sales selling 1,360,416 shares for an estimated $94,355,926.
ANDREW POLOVIN (EVP, Chief Legal Officer) has made 0 purchases and 10 sales selling 43,558 shares for an estimated $2,882,519.
JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 6 sales selling 37,307 shares for an estimated $2,532,550.
RYAN FUKUSHIMA (Chief Executive Officer, Data) has made 0 purchases and 10 sales selling 34,691 shares for an estimated $2,373,358.
ERIK PHELPS (EVP, Chief Admin. Officer) has made 0 purchases and 5 sales selling 14,299 shares for an estimated $881,800.
RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 3 sales selling 4,736 shares for an estimated $291,559.
WAYNE A.I. FREDERICK sold 3,675 shares for an estimated $283,820
JENNIFER A DOUDNA has made 0 purchases and 2 sales selling 2,602 shares for an estimated $188,684.
DAVID R EPSTEIN has made 0 purchases and 3 sales selling 990 shares for an estimated $74,169.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$TEM Hedge Fund Activity

We have seen 249 institutional investors add shares of $TEM stock to their portfolio, and 211 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

GC WEALTH MANAGEMENT RIA, LLC added 6,761,507 shares (+inf%) to their portfolio in Q4 2025, for an estimated $399,266,988
BANK OF AMERICA CORP /DE/ removed 1,268,004 shares (-52.6%) from their portfolio in Q4 2025, for an estimated $74,875,636
BNP PARIBAS FINANCIAL MARKETS removed 1,101,434 shares (-86.4%) from their portfolio in Q4 2025, for an estimated $65,039,677
BAILLIE GIFFORD & CO removed 950,999 shares (-9.8%) from their portfolio in Q4 2025, for an estimated $56,156,490
AQR CAPITAL MANAGEMENT LLC removed 888,879 shares (-98.2%) from their portfolio in Q4 2025, for an estimated $52,488,304
CITADEL ADVISORS LLC added 885,025 shares (+5044.3%) to their portfolio in Q4 2025, for an estimated $52,260,726
D. E. SHAW & CO., INC. removed 847,169 shares (-41.8%) from their portfolio in Q4 2025, for an estimated $50,025,329

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$TEM Government Contracts

We have seen $20,963,166 of award payments to $TEM over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$TEM Congressional Stock Trading

Members of Congress have traded $TEM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TEM stock by members of Congress over the last 6 months:

REPRESENTATIVE NANCY PELOSI purchased up to $100,000 on 01/16.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$TEM Analyst Ratings

Wall Street analysts have issued reports on $TEM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 12/22/2025
BTIG issued a "Buy" rating on 11/25/2025
Morgan Stanley issued a "Overweight" rating on 11/11/2025
HC Wainwright & Co. issued a "Buy" rating on 11/07/2025

To track analyst ratings and price targets for $TEM, check out Quiver Quantitative's $TEM forecast page.

$TEM Price Targets

Multiple analysts have issued price targets for $TEM recently. We have seen 11 analysts offer price targets for $TEM in the last 6 months, with a median target of $75.0.

Here are some recent targets:

Tycho Peterson from Jefferies set a target price of $35.0 on 04/13/2026
Subbu Nambi from Guggenheim set a target price of $60.0 on 03/30/2026
Ryan MacDonald from Needham set a target price of $75.0 on 03/11/2026
Yi Chen from HC Wainwright & Co. set a target price of $95.0 on 03/09/2026
Tejas Savant from Morgan Stanley set a target price of $70.0 on 03/03/2026
Mark Massaro from BTIG set a target price of $90.0 on 02/25/2026
Casey Woodring from JP Morgan set a target price of $60.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.